Video

Dr. Jennifer Miles-Thomas discusses the gender pay gap in urology

Author(s):

Urology Times staff
Conference|LUGPA Annual Meeting

At the 2021 LUGPA Annual Meeting Jennifer Miles-Thomas, MD, FPMRS, president, Urology Of Virginia, participated in a panel discussion titled, “Strategies to Recruit and Retain Female Urologists in your Practice.” In this video, Miles-Thomas discusses the gender pay gap in urology.

Related Videos
Woman talking with doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
Related Content
Second-line cabozantinib shows efficacy in advanced renal cell carcinoma
June 9th 2025

Second-line cabozantinib shows efficacy in advanced renal cell carcinoma

Hannah Clarke
The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC
June 5th 2025

Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC

Hannah Clarke
According to the authors, the mitomycin/BCG regimen could alleviate some of the burden of the global BCG shortage.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Amy L. Shaver, PhD, PharmD, MPH
June 5th 2025

GLP-1 agonist use is rising in men with prostate cancer

Benjamin P. Saylor
In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
Adding niraparib to AAP extends rPFS in HRR-positive mCSPC
June 4th 2025

Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

Hannah Clarke
“AMPLITUDE supports early genomic testing and niraparib plus AAP as a new treatment option for patients with mCSPC and HRR gene alterations," the authors wrote.
© 2025 MJH Life Sciences

All rights reserved.